| 四川科伦博泰生物医药股份有限公司 - H股, 06990.HK - 综合损益表 |
2022-12 |
2021-12 |
| 营业额 |
803,933 |
32,322 |
| 经营溢利 |
-418,550 |
-777,204 |
| 非经营/ 特殊项目 |
0 |
0 |
| 联营公司 |
0 |
0 |
| 除税前经营溢利 |
-567,364 |
-889,795 |
| 税项 |
48,735 |
0 |
| 少数股东权益 |
0 |
0 |
| 股东应占溢利 |
-548,099 |
-822,550 |
| 货币 |
人民币 |
人民币 |
| 单位 |
| 主要项目 |
| 折旧 |
67,364 |
22,914 |
| 利息 |
157,742 |
119,242 |
| 利息拨作发展资本 |
8,928 |
6,651 |
| 处置/重估固定资产 |
0 |
0 |
| 税率(%) |
-8.59 |
|
| 营业额增长(%) |
0.0 |
0.0 |
| 股东应占溢利增长(%) |
0.0 |
0.0 |
| 核数师意见 |
0 |
0 |
说明：1代表无保留意见；2代表保留意见；3代表修改意见
|
We've noticed you're using an ad blocker
We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.
To continue using 88iv.com, please allow this domain on your ad blocker.
We are thanksful for your decisive action.
This notice will be shown again every hour.
Close This Window